AlphAIalphai — Financial news for AI agents
BenzingaJUL 162 min read$LTRN

IBN Initiates Coverage of Lantern Pharma Inc. - Lantern Pharma (NASDAQ:LTRN)

AUSTIN, Texas, July 16, 2025 ( GLOBE NEWSWIRE ) -- via IBN -- Lantern Pharma Inc.

Original reporting
Benzinga · Globe Newswire
Published Jul 16, 2025, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2025, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
IBN Initiates Coverage of Lantern Pharma Inc. - Lantern Pharma (NASDAQ:LTRN) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$LTRNNeutralLow
01

Why it matters

The initiation of coverage by IBN may lead to increased investor awareness, potentially supporting short-term gains for Lantern Pharma.

02

Market read

While the news is relevant within the biotech sector, its immediate impact on broader markets is limited.

03

What to watch

Broader market conditions and upcoming biotech sector developments could overshadow this news.

Timing: Long-term

Background

Lantern Pharma Inc. has been gaining attention in biotech circles, and this coverage could signal increased analyst interest.

Company-level read

Ticker impact

$LTRNNeutralMedium confidence
Context

Neutral sentiment with moderate relevance to current news.

Expected impact

Minimal price change anticipated in the short term.

Evidence & confidence

The neutral sentiment score (0.09) and relevance (0.31) imply limited influence from this coverage.

Market effects

Sector

Potential positive sentiment in the Life Sciences sector due to coverage initiation.

Regional

Limited regional impact expected, primarily affecting US-based biotech stocks.

Global

Minimal global market influence from this news.

Counterpoint

What could challenge this read

The coverage initiation may already be priced in, and the actual impact could be limited.

Key entities

  • Company
    Lantern Pharma Inc.

    A biotech company focused on personalized cancer therapies.

  • Analyst Firm
    IBN

    Financial analyst firm initiating coverage of Lantern Pharma.

Read at source← All news

Related articles

JUL 23
$LTRNMed

Lantern Pharma Receives U.S. Patent Allowance for LP

Lantern Pharma (NASDAQ: LTRN) said the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent covering patient selection and treatment for ovarian, primary liver, kidney and thyroid cancers using LP-184 (zirdafulven). The allowed claims relate to a three-gene biomarker signature (PTGR1, PTPN14, ASPH). Lantern cited a 45% disease control rate at or above the effective dose in Phase 1a and plans multiple Phase 1b/2 studies in 2026.

citybuzz.co3 min
AUG 8
$BKRMed

Baker Hughes extends long-term service deal for Nigeria LNG Train 7

Baker Hughes said it won a 13-year lifecycle services deal with Nigeria LNG for turbomachinery at NLNG’s Train 7 expansion on Bonny Island. The scope covers heavy-duty gas turbines, centrifugal compressors, remote monitoring via Baker Hughes’ digital platform, and local support. Train 7 is expected to raise capacity from 22 to 30 MMtpa.

worldoil.com3 min
AUG 8
$BKRMed

Baker Hughes wins subsea systems contract for Angola's Greater PAJ field

Baker Hughes said it won a contract from Azule Energy to supply subsea production systems for the Greater PAJ ultra-deepwater project offshore Angola. Scope includes horizontal subsea trees, control modules, workover control systems and related equipment plus installation and support. Greater PAJ is expected to start producing in 2029 via an FPSO processing up to 95,000 bpd, with deliveries starting in 2027.

worldoil.com4 min
AUG 8
$WENMed

57-year-old Burger chain closed 28 restaurants, 100s more coming

Wendy’s (WEN) said it closed 28 restaurants and expects to close 5% to 6% of U.S. units (about 289 to 358) in 1H 2026, with possible additional selective closures. The company reported 2Q FY2026 systemwide sales down 6.5% YoY, U.S. systemwide down 8.2%, and U.S. same-restaurant sales down 7%. Wendy’s launched a turnaround plan and withdrew its 2026 outlook.

yahoo.com6 min